Cargando…
Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer
Breast cancer is a major disease affecting women worldwide. A woman has 1 in 8 lifetime risk of developing breast cancer, and morbidity and mortality due to this disease are expected to continue to rise globally. Breast cancer remains a challenging disease due to its heterogeneity, propensity for re...
Autores principales: | Ali, Suhad, Hamam, Dana, Liu, Xueqing, Lebrun, Jean-Jacques |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499354/ https://www.ncbi.nlm.nih.gov/pubmed/36157462 http://dx.doi.org/10.3389/fendo.2022.993570 |
Ejemplares similares
-
Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis
por: Shams, Anwar, et al.
Publicado: (2021) -
Prolactin Pro-Differentiation Pathway in Triple Negative Breast Cancer: Impact on Prognosis and Potential Therapy
por: López-Ozuna, Vanessa M., et al.
Publicado: (2016) -
Prolactin: The Third Hormone in Breast Cancer
por: Schuler, Linda A., et al.
Publicado: (2022) -
Concomitant Expression of Prolactin Receptor and TGFβ Receptors in Breast Cancer: Association with Less Aggressive Phenotype and Favorable Patient Outcome
por: Hachim, Ibrahim Y., et al.
Publicado: (2019) -
Metabolic effects of prolactin
por: Pirchio, Rosa, et al.
Publicado: (2022)